CIP2A overexpression is associated with c-Myc expression in colorectal cancer

Figures & data

Figure 1. Representative images of CIP2A and c-Myc expression in colorectal cancer. (A) CIP2A negative, (B) weakly positive, and (C) strongly positive immunoreactivity. (D) Negative c-Myc cytoplasmic and nuclear immunoreactivity. (E) Strongly positive cytoplasmic c-Myc immunoreactivity, and (F) over 80% positive nuclear c-Myc immunoreactivity. Original magnification was 200x.

Table 1. Association of CIP2A with clinicopathologic variables in a test series with 540 colorectal cancer patients

Clinicopathological variable	CIP2A expression score 0–1			CIP2A expression score 2–3
	n	n	%	n	%	p value*
Age, years
< 65	231	23	10.0	208	90.0	0.785
≥ 65	309	33	10.7	276	89.3
Gender
Male	297	26	8.8	271	91.2	0.173
Female	243	30	12.3	213	87.7
Grade (WHO)
1	18	4	22.2	14	77.8	0.014
2	354	32	9.0	322	91.0
3	145	13	9.0	132	91.0
4	22	6	27.3	16	72.7
Dukes
A	80	13	16.3	67	83.8	0.310
B	192	17	8.9	175	91.1
C	135	13	9.6	122	90.4
D	133	13	9.8	120	90.2
Histologic type
Adeno	482	40	8.3	442	91.7	< 0.0001
Mucinous	58	16	27.6	42	72.4
Location
Colon	302	32	10.6	270	89.4	0.885
Rectum	235	24	10.2	211	89.8

* Chi-square test

Table 2. Association of CIP2A with clinicopathologic variables in a validation series with 212 colorectal cancer patients

Clinicopathological variable	CIP2A expression score 0–1			CIP2A expression score 2–3
	n	n	%	n	%	p value*
Age, years
< 65	97	20	20.6	77	79.4	0.139
≥ 65	115	15	13.0	100	87.0
Gender
Male	131	25	19.1	106	80.9	0.199
Female	81	10	12.3	71	87.7
Grade (WHO)
1	8	4	50.0	4	50.0	0.018
2	159	24	15.1	135	84.9
3	37	5	13.5	32	86.5
4	4	2	50.0	2	50.0
Dukes
A	30	6	20.0	24	80.0	0.232
B	70	9	12.9	61	87.1
C	68	9	13.2	59	86.8
D	42	11	26.2	31	73.8
pT
T1	8	3	37.5	5	62.5	0.024
T2	49	7	14.3	42	85.7
T3	129	16	12.4	113	87.6
T4	20	7	35.0	13	65.0
pN
N0	101	14	13.9	87	86.1	0.097
N1	57	7	12.3	50	87.7
N2	45	12	23.7	33	73.3
pM
M0	163	22	13.5	141	86.5	0.038
M1	41	11	26.8	30	73.2
Histologic type
Adeno	200	32	16.0	168	84.0	0.328
Mucinous	11	3	27.3	8	72.7
Location
Colon	80	11	13.8	69	86.3	0.288
Rectum	123	24	19.5	99	80.5
c-Myc nuclear positivity, %
0–10	63	12	19.0	51	81.0	0.018
11–30	30	0	0	30	100
31–50	37	9	24.3	28	75.7
51–80	47	4	8.5	43	91.5
> 80	28	7	25.0	21	75.0

* Chi-square test

Table 3. Association of CIP2A with molecular biomarkers in a test series with 540 colorectal cancer patients

Clinicopathological variable	CIP2A expression score 0–1			CIP2A expression score 2–3
	n	n	%	n	%	p value*
Ki-67, %
≤ 10	271	29	10.7	242	29.3	0.488
> 10	162	14	8.6	148	91.4
p53, %
≤ 10	388	41	10.6	347	89.4	0.042
> 10	70	2	2.9	68	97.1
EGFR, %
≤ 10	249	30	12.8	219	88.0	0.007
> 10	234	12	5.1	222	94.9

* Chi-square test

Figure 2. Survival analysis for CIP2A and c-Myc expression in colorectal cancer patients. (A) Disease-specific overall survival analysis according to the Kaplan-Meier method for cytoplasmic CIP2A immunoreactivity in the test series (p = 0.270, log-rank test). (B) Disease-specific overall survival analysis according to the Kaplan-Meier method for cytoplasmic c-Myc immunoreactivity in the validation series (p = 0.003, log-rank test).